Current Advances and Material Innovations in the Search for Novel Treatments of Phenylketonuria

• Published in: Advanced healthcare materials p. e2401353
• Main Authors: Delbreil, Philippe, Dhondt, Sofie, Kenaan El Rahbani, Rita Maria, Banquy, Xavier, Mitchell, John J, Brambilla, Davide
• Format: Journal Article
• Language: English
• Published: Germany 31.05.2024
• Subjects: gene therapy; phenylalanine ammonia‐lyase; drug delivery; phenylketonuria; oral delivery
• ISSN: 2192-2659
• DOI: 10.1002/adhm.202401353

Phenylketonuria (PKU) is a genetically inherited disease caused by a mutation of the gene encoding phenylalanine hydroxylase (PAH) and is the most common inborn error of amino acid metabolism. A deficiency of PAH leads to increased blood and brain levels of phenylalanine (Phe), which may cause permanent neurocognitive symptoms and developmental delays if untreated. Current management strategies for PKU consist of early detection through neonatal screening and implementation of a restrictive diet with minimal amounts of natural protein in combination with Phe-free supplements and low-protein foods to meet nutritional requirements. For milder forms of PKU, oral treatment with synthetic sapropterin (BH4), the cofactor of PAH, may improve metabolic control of Phe and allow for more natural protein to be included in the patient's diet. For more severe forms, daily injections of pegvaliase, a PEGylated variant of phenylalanine ammonia-lyase (PAL), may allow for normalization of blood Phe levels. However, the latter treatment has considerable drawbacks, notably a strong immunogenicity of the exogenous enzyme and the attached polymeric chains. Research for novel therapies of PKU makes use of innovative materials for drug delivery and state-of-the-art protein engineering techniques to develop treatments which are safer, more effective, and potentially permanent.